regenerative cell therapy News
-
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate to enter clinical investigation for the treatment of epilepsy Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of ...
-
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Locust Walk Stem Cell Tx Conference, which is being organized in partnership with the Harvard Stem Cell Institute, ...
-
InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy
InGeneron, Inc., a regenerative medicine and cell therapy company, announced today the enrollment of the first patients in a pivotal study evaluating InGeneron’s cell therapy as a way to treat partial thickness rotator cuff tears involving a partial tear in the supraspinatus tendon. The primary goal of the double-blinded, multi-center trial is to demonstrate the effectiveness of the ...
-
InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics
InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called “stem cell therapy”, to treat orthopedic indications. This newly released paper, titled “Perspective: Why and how to use the body’s own stem cells for regeneration in musculoskeletal disorders: a primer“, was ...
-
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of preclinical data from its lead inhibitory neuron cell therapy candidate, NRTX-1001. NRTX-1001 is being evaluated in a Phase 1/2 clinical trial in people with drug-resistant mesial temporal lobe epilepsy. The data are being ...
-
Celixir appoints Dr Mubasher Sheikh as Chairman of the Board
Celixir, a private company discovering and developing life-saving cell therapies, announces the appointment of Dr Mubasher Sheikh (Chairman), Professor Fiona Murray CBE, Professor Gary Pisano, Conor Kehoe and Professor Sir Martin Evans as Non-Executive Directors. Celixir recently announced approval of a clinical trial application from the UK’s Medicines and Healthcare Products Regulatory ...
By Celixir plc
-
InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure
InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform. A newly-released research paper published in the World Journal of Stem Cells provides missing pieces of evidence for a fundamental change in the treatment of chronic ...
-
InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, autologous, adipose derived regenerative cells (UA-ADRCs). This newly-released research paper, titled “First ...
-
Big Data Meets Big Biology in San Diego: Some Takeaways
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. Today, scientists are amassing a new arsenal of ...
-
World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science Officer Dr. Kristin Comella’s interview with Ben Pakulski — a world bodybuilding expert who last year received autologous stem cell therapy that successfully treated torn muscles. ...
-
American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears
InGeneron, Inc., a clinical stage biotechnology company, today announced that the American Medical Association’s (AMA) Current Procedural Terminology (CPT®) Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tears. The newly published codes (0717T, 0718T) ...
-
DiscGenics Announces Publication of Preclinical Data for Disc Degeneration Treatment in The Spine Journal
Salt Lake City, UT – September 24, 2019 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the online publication of a study in The Spine Journal [1] that summarizes the results of preclinical ...
-
Japanese Clinical Study of DiscGenics` Cell Therapy for Disc Degeneration Passes Initial Safety Review
Salt Lake City, UT and Tokyo, Japan – January 7, 2020 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has passed the initial planned safety review of its double-blinded clinical study evaluating ...
-
RepliCel Announces Material Patent Milestones
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce the filing of a new patent application covering novel aspects of the DermaPrecise™ product portfolio as well ...
-
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Phase 1/2 first-in-human U.S. clinical study of IDCT, an allogeneic, injectable Discogenic Cell therapy for degenerative disc ...
-
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of ...
-
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year BlueRock Therapeutics to continue to operate as an independent company Bayer AG and BlueRock Therapeutics today announced an agreement ...
-
Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals
The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...
By Poietis
-
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months. Salt Lake City, UT – February 25, 2022 – ...
-
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you